Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT IO-001: NKTR-214 + Nivolumab vs Nivolumab in Advanced Melanoma
NCT03635983Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Primary completion
- Nov 2021
- Modality
- Cytokines & Interferons
- Countries
- 27
01
Overview
A Phase 3 trial of bempegaldesleukin in melanoma, sponsored by Bristol Myers Squibb. Started Sep 2018; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03635983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635983.